ATE164828T1 - 3,3-diphenylpropylamine, ihre verwendung und herstellung - Google Patents

3,3-diphenylpropylamine, ihre verwendung und herstellung

Info

Publication number
ATE164828T1
ATE164828T1 AT93924876T AT93924876T ATE164828T1 AT E164828 T1 ATE164828 T1 AT E164828T1 AT 93924876 T AT93924876 T AT 93924876T AT 93924876 T AT93924876 T AT 93924876T AT E164828 T1 ATE164828 T1 AT E164828T1
Authority
AT
Austria
Prior art keywords
compounds
methyl
formula
diphenylpropylamines
relates
Prior art date
Application number
AT93924876T
Other languages
English (en)
Inventor
Rolf Arne Johansson
Pinchas Moses
Lisbeth Nilverbant
Bengt Ake Sparf
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20387730&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE164828(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of ATE164828T1 publication Critical patent/ATE164828T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Photoreceptors In Electrophotography (AREA)
AT93924876T 1992-11-06 1993-11-05 3,3-diphenylpropylamine, ihre verwendung und herstellung ATE164828T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9203318A SE9203318D0 (sv) 1992-11-06 1992-11-06 Novel 3,3-diphenylpropylamines, their use and preparation

Publications (1)

Publication Number Publication Date
ATE164828T1 true ATE164828T1 (de) 1998-04-15

Family

ID=20387730

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93924876T ATE164828T1 (de) 1992-11-06 1993-11-05 3,3-diphenylpropylamine, ihre verwendung und herstellung

Country Status (15)

Country Link
US (4) USRE40851E1 (de)
EP (1) EP0667852B1 (de)
JP (1) JP3343256B2 (de)
AT (1) ATE164828T1 (de)
AU (1) AU672458B2 (de)
CA (1) CA2148827C (de)
DE (1) DE69317898T2 (de)
DK (1) DK0667852T3 (de)
ES (1) ES2117155T3 (de)
FI (1) FI120256B (de)
HK (1) HK1006349A1 (de)
HU (1) HU224916B1 (de)
NO (1) NO305477B1 (de)
SE (1) SE9203318D0 (de)
WO (1) WO1994011337A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
WO1998000140A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r)-trihexyphenidyl
DE69720518T2 (de) * 1996-12-02 2004-02-26 Kyorin Pharmaceutical Co., Ltd. Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (de) 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
HUP0100437A3 (en) 1998-08-27 2002-08-28 Pharmacia And Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
EE05191B1 (et) 1999-11-11 2009-08-17 Pharmacia Ab Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
EP1277737A4 (de) 2000-03-24 2003-05-07 Meiji Seika Kaisha DIPHENYLALKYLAMIN-DERIVATE ALS AGONISTEN DES OPIOID -g(d)-REZEPTORS
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
US6951654B2 (en) * 2001-03-27 2005-10-04 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
PT1461306E (pt) * 2001-10-26 2009-04-01 Pharmacia & Upjohn Co Llc Compostos de amónio quaternário
CA2464217A1 (en) * 2001-11-05 2003-05-15 Pharmacia & Upjohn Company Antimuscarinic aerosol
WO2003039524A1 (en) * 2001-11-09 2003-05-15 Pharmacia Ab Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US20030152624A1 (en) * 2001-12-20 2003-08-14 Aldrich Dale S. Controlled release dosage form having improved drug release properties
EP2266590A3 (de) 2002-02-22 2011-04-20 Shire LLC Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
US7005449B2 (en) * 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
MXPA05000434A (es) * 2002-07-08 2005-04-19 Ranbaxy Lab Ltd Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP1565187A4 (de) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs undverwandte verfahren
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100436414C (zh) * 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
MXPA05011509A (es) 2003-04-25 2005-12-15 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) sustituidas con halogenos que presentan actividad antimuscarinica.
CA2522888C (en) * 2003-05-23 2012-07-17 Bridge Pharma, Inc. Smooth muscle spasmolytic agents
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
CA2551501C (en) * 2003-12-24 2012-05-29 Cipla Limited Tolterodine, compositions and uses thereof, and preparation of the same
BRPI0507891A (pt) 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
EP1629834A1 (de) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung
EP1828126A1 (de) * 2004-12-15 2007-09-05 Ranbaxy Laboratories Limited Säureadditionssalze von antagonisten des muskarinrezeptors
WO2006074478A1 (en) * 2005-01-10 2006-07-13 Teva Pharmaceuticals Usa, Inc. Substantially pure tolterodine tartrate and process for preparing thereof
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
DK1885187T3 (da) 2005-05-13 2013-12-09 Novartis Ag Fremgangsmåde til behandling af lægemiddelresistent cancer
AU2006327882A1 (en) * 2005-12-20 2007-06-28 Pfizer Products Inc. Pharmaceutical combination for the treatment of LUTS comprising a PDE5 inhibitor and a muscarinic antagonist
WO2007107828A2 (en) 2006-03-20 2007-09-27 Pfizer Limited Amine derivatives
JP5257353B2 (ja) * 2006-05-31 2013-08-07 シュウォーツ ファーマ リミテッド 置換ヒドロキシメチルフェノールの新規な合成
EP1862449A1 (de) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. Verkürzte Synthese von substituierten Hydroxymethylphenolen
IES20060424A2 (en) 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
WO2007140986A1 (en) 2006-06-09 2007-12-13 Schwarz Pharma Ltd Synthesis of phenolic esters of hydroxymethyl phenols
IES20060435A2 (en) 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
US7982058B2 (en) 2006-06-12 2011-07-19 Ucb Pharma Gmbh Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof
US8193391B2 (en) 2006-06-20 2012-06-05 Lek Pharmaceuticals, D.D. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N-alkyl-3-phenylpropylamines
WO2009037569A2 (en) * 2007-09-21 2009-03-26 Actavis Group Ptc Ehf An improved process for the preparation of fesoterodine
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
KR20120014583A (ko) * 2009-05-11 2012-02-17 라티오팜 게엠베하 타르타르산 염 형태의 데스페소테로딘
IT1394219B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
IT1394217B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
SI2281801T1 (sl) * 2009-07-27 2014-04-30 Crystal Pharma, S.A.U. Postopek za pridobivanje 3,3-diphenilpropilamina
IT1396373B1 (it) 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
EP2364966A1 (de) 2010-03-09 2011-09-14 LEK Pharmaceuticals d.d. Verfahren zur Herstellung von 3-(2-hydroxy-5-substituierten phenyl)-3-phenylpropylaminen, Zwischenprodukte zur Herstellung von Hydroxytolterodin
WO2011141932A2 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
WO2011145019A1 (en) * 2010-05-17 2011-11-24 Orchid Chemicals And Pharmaceuticals Limited Improved process for diphenylpropylamine derivatives
IT1401451B1 (it) 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
CA2873721C (en) 2012-05-04 2021-06-22 Crystal Pharma, S.A.U. Process for the preparation of optically active 3,3-diphenylpropylamines
PL2760822T3 (pl) 2012-06-14 2016-09-30 Sole desfezoterodyny
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2016148444A1 (ko) * 2015-03-17 2016-09-22 제이더블유중외제약 주식회사 신규 데스페소테로딘 유도체, 이의 약제학적으로 허용되는 염 및 이를 포함하는 약제학적 조성물
WO2017137955A1 (en) 2016-02-14 2017-08-17 Celestis Pharmaceuticals Pvt. Ltd. Novel (r) and rac 3-(2-(allyloxy)-5-methylphenyl)-n,n-diisopropyl-3- phenylpropan-1-amine and its use for synthesis of (r) and rac-2-(3- (diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol
CN110372571B (zh) 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111894A (de) 1962-11-15
GB1169944A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof
GB1169945A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
US4139537A (en) 1976-06-29 1979-02-13 Cooper Laboratories, Inc. 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma

Also Published As

Publication number Publication date
NO951775L (no) 1995-05-05
HK1006349A1 (en) 1999-02-19
FI952179A (fi) 1995-05-05
EP0667852B1 (de) 1998-04-08
CA2148827A1 (en) 1994-05-26
JPH08503208A (ja) 1996-04-09
DE69317898D1 (de) 1998-05-14
HU9501329D0 (en) 1995-06-28
AU672458B2 (en) 1996-10-03
JP3343256B2 (ja) 2002-11-11
US5559269A (en) 1996-09-24
EP0667852A1 (de) 1995-08-23
ES2117155T3 (es) 1998-08-01
CA2148827C (en) 2005-01-04
FI120256B (fi) 2009-08-31
NO305477B1 (no) 1999-06-07
HUT72742A (en) 1996-05-28
SE9203318D0 (sv) 1992-11-06
HU224916B1 (en) 2006-04-28
FI952179A0 (fi) 1995-05-05
NO951775D0 (no) 1995-05-05
DK0667852T3 (da) 1999-01-11
USRE40851E1 (en) 2009-07-14
WO1994011337A1 (en) 1994-05-26
USRE39667E1 (en) 2007-05-29
AU5438094A (en) 1994-06-08
US5686464A (en) 1997-11-11
DE69317898T2 (de) 1998-10-15

Similar Documents

Publication Publication Date Title
DE69317898T2 (de) 3,3-diphenylpropylamine, ihre verwendung und herstellung
DE68900180D1 (de) Amine, ihre verwendung und herstellung.
ZA932168B (en) Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
ATE143957T1 (de) Aminoalkylchomone, verfahren für ihre herstellung und die enthaltende pharmazeutische zusammensetzungen
DK0574783T3 (da) Asymmetrisk hydrogenering
DE3381885D1 (de) Piperidinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ZA933942B (en) Pyrrolothienopyrazine compounds, processes for the preparation thereof and pharmaceutical compositions containing them
KR880009930A (ko) 헤테로시클릭 화합물, 이의 제조방법 및 약학적 제형

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification